Bacil Pharma Q1 Results: Net profit turns to loss of ₹1.61 lakh
Bacil Pharma Ltd posted a Q1FY27 net loss of ₹1.61 lakh, reversing a ₹62.16 lakh profit from the prior quarter. Revenue dropped to ₹8.91 lakh as other income declined. Deferred tax expenses of ₹8.25 lakh outweighed pre-tax profits, driving the loss.
*this image is generated using AI for illustrative purposes only.
Bacil Pharma Limited reported a net loss of ₹1.61 lakh for the quarter ended June 30, 2026, marking a significant deterioration from the profit of ₹62.16 lakh recorded in the previous quarter. The company’s total revenue fell to ₹8.91 lakh from ₹11.34 lakh, driven by a decline in other income. This shift highlights volatility in the firm’s earnings structure, where non-operating items heavily influence the bottom line.
The Board of Directors approved the unaudited financial results on August 12, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Sarang Shivajirao Chavan and Associates, in accordance with Standard on Review Engagements (SRE) 2410. The financial statements were prepared in compliance with Indian Accounting Standards (Ind AS).
Financial Performance Overview
The company generated no revenue from operations during the quarter, relying entirely on other income. Total expenses stood at ₹2.27 lakh, comprising employee benefits expense of ₹0.72 lakh and other expenses of ₹1.55 lakh. Before tax, the company recorded a profit of ₹6.64 lakh. However, a deferred tax expense of ₹8.25 lakh pushed the post-tax result into negative territory.
| Particulars | Q1 FY27 (₹ in Lakhs) | Q4 FY26 (₹ in Lakhs) | Q1 FY26 (₹ in Lakhs) |
|---|---|---|---|
| Revenue from Operations | - | - | - |
| Other Income | 8.91 | 11.34 | 100.30 |
| Total Revenue | 8.91 | 11.34 | 100.30 |
| Employee Benefits Expense | 0.72 | 0.00 | 3.00 |
| Other Expenses | 1.55 | 7.45 | 7.90 |
| Total Expenses | 2.27 | 7.45 | 10.90 |
| Profit Before Tax | 6.64 | 3.89 | 89.40 |
| Deferred Tax Expense | 8.25 | 58.27 | - |
| Net Profit/(Loss) | (1.61) | 62.16 | 66.90 |
What the Numbers Show
The primary driver of the quarterly loss was the deferred tax expense of ₹8.25 lakh, which exceeded the pre-tax profit of ₹6.64 lakh. In contrast, the previous quarter saw a much higher deferred tax charge of ₹58.27 lakh against a lower pre-tax profit of ₹3.89 lakh, yet it still resulted in a net profit due to other comprehensive income adjustments or timing differences not fully detailed in the summary figures. The current quarter’s basic earnings per share (EPS) stood at ₹0.22, down from ₹0.44 in the preceding quarter. The company’s paid-up equity share capital remained unchanged at ₹1,397.03 lakh.
The limited review report confirmed that the unaudited financial results are free of material misstatement based on the procedures performed. The company operates in a single reportable segment: primary pharmaceutical business.
Historical Stock Returns for Bacil Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.96% | -26.35% | -63.19% | -67.86% | -63.17% | +107.67% |
What specific operational initiatives is Bacil Pharma undertaking to generate revenue from its core pharmaceutical business, given it reported zero revenue from operations this quarter?
How will the significant deferred tax expense of ₹8.25 lakh impact the company's cash flow and working capital in the upcoming quarters?
Is management planning to restructure its income sources to reduce reliance on volatile 'other income' and stabilize earnings?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
